475 related articles for article (PubMed ID: 25465343)
1. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
[TBL] [Abstract][Full Text] [Related]
2. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
5. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
Yu S; Shabihkhani M; Yang D; Thara E; Senagore A; Lenz HJ; Sadeghi S; Barzi A
Clin Colorectal Cancer; 2013 Dec; 12(4):275-9. PubMed ID: 24188686
[TBL] [Abstract][Full Text] [Related]
6. Time to adjuvant chemotherapy and survival outcomes among patients with stage 2 to 3 rectal cancer treated with preoperative chemoradiation.
Gresham G; Cheung WY; Speers C; Woods R; Kennecke H
Clin Colorectal Cancer; 2015 Mar; 14(1):41-5. PubMed ID: 25548075
[TBL] [Abstract][Full Text] [Related]
7. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
8. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
9. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
11. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
12. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
van Gils CW; Koopman M; Mol L; Redekop WK; Uyl-de Groot CA; Punt CJ
Acta Oncol; 2012 Jan; 51(1):57-64. PubMed ID: 22122695
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
Aspinall SL; Good CB; Zhao X; Cunningham FE; Heron BB; Geraci M; Passero V; Stone RA; Smith KJ; Rogers R; Shields J; Sartore M; Boyle DP; Giberti S; Szymanski J; Smith D; Ha A; Sessions J; Depcinski S; Fishco S; Molina I; Lepir T; Jean C; Cruz-Diaz L; Motta J; Calderon-Vargas R; Maland J; Keefe S; Tague M; Leone A; Glovack B; Kaplan B; Cosgriff S; Kaster L; Tonnu-Mihara I; Nguyen K; Carmichael J; Clifford L; Lu K; Chatta G
BMC Cancer; 2015 Feb; 15():62. PubMed ID: 25884851
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
[TBL] [Abstract][Full Text] [Related]
18. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?
Bayraktar UD; Chen E; Bayraktar S; Sands LR; Marchetti F; Montero AJ; Rocha-Lima CM
Cancer; 2011 Jun; 117(11):2364-70. PubMed ID: 24048783
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
Kim CA; Spratlin JL; Armstrong DE; Ghosh S; Mulder KE
Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
[TBL] [Abstract][Full Text] [Related]
20. [Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study].
Mondaca S; Villalón C; Leal JL; Zúñiga Á; Bellolio F; Padilla O; Palma S; Garrido M; Nervi B
Rev Med Chil; 2016 Feb; 144(2):145-51. PubMed ID: 27092667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
